Linz

• A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition Recruiting
  2025-520825-19-00 5 2025-12-16 IgAN is Primary Immunoglobulin A Nephropathy (IgAN) (also known as Ber
• A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic … Recruiting
  2025-522860-34-00 5 2025-12-16 Chronic lymphocytic leukemia (CLL)
• A study to evaluate the impact on metastases-free survival with the addition of saruparib vs placebo to a standard radiotherapy androgen dep … Recruiting
  2024-513586-39-00 5 2025-12-10 Prostate Cancer
• A Study to compare RLY-2608 + Fulvestrant with Capivasertib + Fulvestrant in people with PIK3CA-mutated, hormone-receptor positive, HER2-neg … Recruiting
  2025-523083-21-00 5 2025-12-08 PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor
• A clinical study of belzutifan and zanzalintinib in people with advanced kidney cancer (MK-6482-033) Recruiting
  2024-517136-21-00 5 2025-12-05 Renal Cell Carcinoma
• A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis Recruiting
  2025-521242-26-00 4 2025-11-27 Moderately to Severely Active Ulcerative Colitis
• A Study of BMS-986504 in Combination with Pembrolizumab Plus Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line M … Recruiting
  2025-521511-40-00 10 2025-11-18 metastatic non-small cell lung cancer
• Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator's Choice in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Recruiting
  2025-520555-89-00 5 2025-11-14 Metastatic castration-resistant prostate cancer (mCRPC)
• Study to Evaluate Plozasiran in Adults with Severe Hypertriglyceridemia at high risk of Acute Pancreatitis (SHASTA-5 Study) Recruiting
  2024-518206-40-00 5 2025-11-03 Severe hypertriglyceridemia (SHTG)
• – IKF/AIO-QUINTIS – A Randomized Phase II Trial Evaluating Fruquintinib in Combination with Tislelizumab in Microsatellite Stable / Profici … Recruiting
  2024-519929-38-00 4 2025-10-27 Metastatic Colorectal Cancer without liver metastases
• Phase IIIb Study of 36-Week Refill Exchanges of Port Delivery System with Ranibizumab in nAMD Recruiting
  2024-516924-32-00 5 2025-10-17 Neovascular Age-Related Macular Degeneration (nAMD)
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting
  2024-516652-18-00 5 2025-10-10 Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
• Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Platinum Resistant Ovarian Cancer Recruiting
  2024-514822-21-00 5 2025-10-02 Platinum-resistant Ovarian Cancer
• A Randomized, Open-Label, Controlled Phase 3 Study Comparing Daratumumab, Lenalidomide and Dexamethasone Induction followed by Linvoseltamab … Recruiting
  2024-519827-16-00 5 2025-09-30 Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients
• A Phase 3 study of NBTXR3 with or without cetuximab in LA-HNSCC Recruiting
  2024-520386-31-00 5 2025-09-22 Locally Advanced Head & Neck Squamous Cell Carcinoma
• CATALINA-2: A Phase 2 Study of TORL-1-23 in Advanced Ovarian Cancer Recruiting
  2024-517190-24-00 4 2025-09-16 Peritoneal Cancer
• ABCSG 63 / ERIKA: Elacestrant and RIbociclib in Ki67-tested endocrine responsive breAst cancer: An open-label, two-arm, randomized, phase I … Recruiting
  2023-505758-17-00 4 2025-08-21 endocrine-responsive HER2-negative early breast cancer
• A trial comparing the treatment of rilvegostomig with fluoropyrimidine and trastuzumab deruxtecan to the standard treatment in patients with … Recruiting
  2024-512583-57-00 5 2025-07-30 HER2-positive locally advanced or metastatic gastric or gastroesophage
• A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia Recruiting
  2024-520154-38-00 5 2025-07-29 Acute Myeloid Luekemia
• Phase 3 Study of I-DXd Versus Docetaxel in mCRPC Recruiting
  2024-517423-40-00 5 2025-06-23 Metastatic Castration-Resistant Prostate Cancer
• BIOmarker driven intensification of cardiovascular RISK factor management in patients with high risk for recurrent cardiovascular EVENTs The … Recruiting
  2024-511950-35-00 5 2025-06-12 Acute Myocardial Infarction
• Study of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Unt … Recruiting
  2024-515698-85-00 5 2025-06-12 Locally Advanced or Metastatic Non-small Cell Lung Cancer
• Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Smal … Recruiting
  2024-512302-25-00 5 2025-06-06 Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
• A Study to Compare the Efficacy and Safety of Vedolizumab With and Without Upadacitinib in Adults With Moderately to Severely Active Crohn's … Recruiting
  2023-509391-42-00 11 2025-06-02 Chron's Disease

Showing 97–120 of 401 trials